See a study design of a phase 2 trial evaluating efficacy and safety of a humanized anti-HER2 monoclonal antibody-drug conjugate in patients with HER2-expressing metastatic or locally advanced unresectable non-small cell #LungCancer at #WCLC24 P2.10A.01 bit.ly/3WpAjv9

Read results from a study comparing the efficacy and safety of a third generation ALK inhibitor vs second generation ALK inhibitors using matching-adjusted indirect comparisons in patients with ALK+ advanced/metastatic non-small cell #LungCancer bit.ly/3ATggOE

See results from a real-world study evaluating contemporary sequencing patterns & effectiveness of 1st-line & 2nd-line therapies in pts who received 2nd-generation ALK TKIs in the 1st-line treatment of ALK+ metastatic non-small cell #LungCancer in the U.S. bit.ly/3AdJ5Vn

At #WCLC24, see results from a post-hoc analysis of a phase 3 study exploring kinetics of AEs associated with an ALK inhibitor and management practices followed to optimize outcomes for ALK+ advanced NSCLC patients after 5 years of follow up #LungCancer bit.ly/4fpdFvp

See latest results of a safety analysis from an ongoing phase 2 study in patients with BRAF V600E-mutant metastatic non-small cell #LungCancer treated with a BRAF inhibitor + a MEK inhibitor #WCLC24 MA06.13 bit.ly/3YGVcVt

At #WCLC24, see results from a study evaluating the patterns of progression with an ALK inhibitor and the efficacy of subsequent treatments following 5 years follow-up in patients with advanced ALK+ non-small cell #LungCancer MA06.07 bit.ly/3M4ssyp

Listen to this podcast episode discussing the clinical implications of a phase 2 study evaluating the efficacy & safety of a BRAF inhibitor + MEK inhibitor in patients with BRAF V600E-mutant metastatic non-small cell #LungCancer bit.ly/3AWHsMj

Pfizer is proud to be a part of #ESMO24! Join us throughout the congress as we share our latest oncology research. bit.ly/4fZhuro

Today kicks off #ESMO24! Join us throughout the congress as we share our latest poster presentations across our oncology portfolio: bit.ly/4fZhuro

At #ESMO24, check out an oral presentation on interim results from a phase 1 study of a PD-L1-directed antibody-drug conjugate in patients with PD-L1+ solid #tumors: bit.ly/4dCRTmH

Join us at #ESMO24, for an oral presentation on our phase 2 study in cancer #cachexia Click here to learn more: bit.ly/4e8Cv1d

At #ESMO24, check out our mini oral presentation on a BRAF inhibitor + EGFR inhibitor + chemo in patients with BRAF V600E-mutant metastatic #ColorectalCancer bit.ly/3MLWAPr

We’re proud to share a mini oral presentation of an update of an ongoing phase 2 study in patients with BRAF V600E-mutant metastatic non-small cell #LungCancer at #ESMO24: bit.ly/4dFZYqK

At #ESMO24, see our oral presentation on a phase 1b/2 study evaluating a novel combination regiment in HR+/HER2- metastatic #BreastCancer and advanced solid #Tumors: bit.ly/3XzqLj3

Are you attending #ESMO24? Check out our mini oral presentation on a cohort of a phase 2 study of an antibody-drug conjugate + immunotherapy in advanced #UrothelialCarcinoma: bit.ly/4cRStf3

At #ESMO24, see results of an exploratory analysis of our phase 3 study of an antibody-drug conjugate + immunotherapy in patients with #UrothelialCarcinoma bit.ly/4gbJ0lH

Read results from a study evaluating the association of HSD3B1 genotype with outcomes in a phase 3 trial in patients with metastatic hormone-sensitive #ProstateCancer treated with an androgen receptor inhibitor + androgen deprivation therapy bit.ly/3yYCtKw

Read results from a cross-sectional survey evaluating patient preferences for attributes of androgen deprivation therapy in #ProstateCancer bit.ly/3yXZZqO

See results from a US-based retrospective study evaluating survival in patients with HER2- and HER2+ metastatic #BreastCancer before and after CDK4/6 inhibitor introduction bit.ly/3XwXuoX

Thank you to all who attended #WCLC24! In case you missed it, explore our latest lung cancer research presented at the congress: here: bit.ly/3Xx11Ci